Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Abediterol

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Abediterol
Clinical data
Routes of
administration		Inhalation
ATC code
  • None
Pharmacokinetic data
Eliminationhalf-life24.3 hours[1]
Identifiers
  • 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC25H30F2N2O4
Molar mass460.522 g·mol−1
3D model (JSmol)
  • FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
  • InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 checkY
  • Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N checkY

Abediterol (INN;[2] development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment ofasthma andchronic obstructive pulmonary disease (COPD), but it has never been marketed.

History

[edit]

Abediterol was underdevelopment by the Spanish pharmaceutical companyAlmirall and reachedPhase II clinical trials,[3][4] but was discontinued in 2021.[5] Its coformulation withmometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.[6]

Mechanism of action

[edit]

Abediterol is anultra-long-acting β2 agonist (ultra-LABA).[7][8][9]

References

[edit]
  1. ^Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S (December 2014). "First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist".Journal of Clinical Pharmacology.54 (12):1347–53.doi:10.1002/jcph.355.PMID 24989946.S2CID 20959248.
  2. ^"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104"(PDF).WHO Drug Information.24 (1): 352. 2010. Retrieved25 March 2016.
  3. ^Product development pipeline,Almirall
  4. ^"AdisInsight: Abediterol".Adis Insight. Springer International Publishing AG. Retrieved25 March 2016.
  5. ^"Abediterol".Adis Insight. Springer International Publishing AG. Retrieved6 February 2024.
  6. ^"AdisInsight: Abediterol/mometasone".Adis Insight. Springer International Publishing AG. Retrieved6 February 2024.
  7. ^Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S (October 2014)."Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma".Respiratory Medicine.108 (10):1424–9.doi:10.1016/j.rmed.2014.08.005.PMID 25256258.
  8. ^WO2006122788A1, Duran, Carlos Puig; Crespo, Maria Isabel Crespo & Laria, Julio Cesar Castro Palomino et al., "Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor", issued 2006-11-23 
  9. ^WO2010094484A1, Ruf, Thorsten & Montejo, Eric Massana, "5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases", issued 2010-08-26 
Adrenergics,inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthinePDE4 inhibitors
Others/unknown
Combination products
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)


Stub icon

Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Abediterol&oldid=1329472548"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp